Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of intravitreal IBI302 in diabetic macular edema
CTR20251163Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efdamrofusp alfa in diabetic macular edema (DME), sponsored by InnoCare Pharma. Started Apr 2025; status: active.
02
Drugs
efdamrofusp alfa
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20251163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251163.